Cargando…
Tenofovir Hot-Melt Granulation using Gelucire(®) to Develop Sustained-Release Vaginal Systems for Weekly Protection against Sexual Transmission of HIV
Hot-melt granulation is a technique used to obtain granules by dispersing a drug in polymers at a high temperature. Tenofovir, an antiretroviral drug with proven activity as a vaginal microbicide, was dispersed in melted Gelucire(®) (or a mixture of different Gelucire(®)) to obtain drug-loaded granu...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470605/ https://www.ncbi.nlm.nih.gov/pubmed/30897790 http://dx.doi.org/10.3390/pharmaceutics11030137 |
_version_ | 1783411835887681536 |
---|---|
author | Notario-Pérez, Fernando Cazorla-Luna, Raúl Martín-Illana, Araceli Ruiz-Caro, Roberto Peña, Juan Veiga, María-Dolores |
author_facet | Notario-Pérez, Fernando Cazorla-Luna, Raúl Martín-Illana, Araceli Ruiz-Caro, Roberto Peña, Juan Veiga, María-Dolores |
author_sort | Notario-Pérez, Fernando |
collection | PubMed |
description | Hot-melt granulation is a technique used to obtain granules by dispersing a drug in polymers at a high temperature. Tenofovir, an antiretroviral drug with proven activity as a vaginal microbicide, was dispersed in melted Gelucire(®) (or a mixture of different Gelucire(®)) to obtain drug-loaded granules. Studies performed on the granules proved that the drug is not altered in the hot-melt granulation process. The granules obtained were included in a matrix formed by the hydrophilic polymers hydroxypropylmethylcellulose and chitosan to obtain vaginal tablets that combine different mechanisms of controlled release: The Gelucire(®) needs to soften to allow the release of the Tenofovir, and the hydrophilic polymers must form a gel so the drug can diffuse through it. The studies performed with the tablets were swelling behavior, Tenofovir release, and ex vivo mucoadhesion. The tablets containing granules obtained with Tenofovir and Gelucire(®) 43/01 in a ratio of 1:2 in a matrix formed by hydroxypropylmethylcellulose and chitosan in a ratio of 1.9:1 were selected as the optimal formulation, since they release Tenofovir in a sustained manner over 216h and remain attached to the vaginal mucosa throughout. A weekly administration of these tablets would therefore offer women protection against the sexual transmission of HIV. |
format | Online Article Text |
id | pubmed-6470605 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64706052019-04-27 Tenofovir Hot-Melt Granulation using Gelucire(®) to Develop Sustained-Release Vaginal Systems for Weekly Protection against Sexual Transmission of HIV Notario-Pérez, Fernando Cazorla-Luna, Raúl Martín-Illana, Araceli Ruiz-Caro, Roberto Peña, Juan Veiga, María-Dolores Pharmaceutics Article Hot-melt granulation is a technique used to obtain granules by dispersing a drug in polymers at a high temperature. Tenofovir, an antiretroviral drug with proven activity as a vaginal microbicide, was dispersed in melted Gelucire(®) (or a mixture of different Gelucire(®)) to obtain drug-loaded granules. Studies performed on the granules proved that the drug is not altered in the hot-melt granulation process. The granules obtained were included in a matrix formed by the hydrophilic polymers hydroxypropylmethylcellulose and chitosan to obtain vaginal tablets that combine different mechanisms of controlled release: The Gelucire(®) needs to soften to allow the release of the Tenofovir, and the hydrophilic polymers must form a gel so the drug can diffuse through it. The studies performed with the tablets were swelling behavior, Tenofovir release, and ex vivo mucoadhesion. The tablets containing granules obtained with Tenofovir and Gelucire(®) 43/01 in a ratio of 1:2 in a matrix formed by hydroxypropylmethylcellulose and chitosan in a ratio of 1.9:1 were selected as the optimal formulation, since they release Tenofovir in a sustained manner over 216h and remain attached to the vaginal mucosa throughout. A weekly administration of these tablets would therefore offer women protection against the sexual transmission of HIV. MDPI 2019-03-20 /pmc/articles/PMC6470605/ /pubmed/30897790 http://dx.doi.org/10.3390/pharmaceutics11030137 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Notario-Pérez, Fernando Cazorla-Luna, Raúl Martín-Illana, Araceli Ruiz-Caro, Roberto Peña, Juan Veiga, María-Dolores Tenofovir Hot-Melt Granulation using Gelucire(®) to Develop Sustained-Release Vaginal Systems for Weekly Protection against Sexual Transmission of HIV |
title | Tenofovir Hot-Melt Granulation using Gelucire(®) to Develop Sustained-Release Vaginal Systems for Weekly Protection against Sexual Transmission of HIV |
title_full | Tenofovir Hot-Melt Granulation using Gelucire(®) to Develop Sustained-Release Vaginal Systems for Weekly Protection against Sexual Transmission of HIV |
title_fullStr | Tenofovir Hot-Melt Granulation using Gelucire(®) to Develop Sustained-Release Vaginal Systems for Weekly Protection against Sexual Transmission of HIV |
title_full_unstemmed | Tenofovir Hot-Melt Granulation using Gelucire(®) to Develop Sustained-Release Vaginal Systems for Weekly Protection against Sexual Transmission of HIV |
title_short | Tenofovir Hot-Melt Granulation using Gelucire(®) to Develop Sustained-Release Vaginal Systems for Weekly Protection against Sexual Transmission of HIV |
title_sort | tenofovir hot-melt granulation using gelucire(®) to develop sustained-release vaginal systems for weekly protection against sexual transmission of hiv |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470605/ https://www.ncbi.nlm.nih.gov/pubmed/30897790 http://dx.doi.org/10.3390/pharmaceutics11030137 |
work_keys_str_mv | AT notarioperezfernando tenofovirhotmeltgranulationusinggeluciretodevelopsustainedreleasevaginalsystemsforweeklyprotectionagainstsexualtransmissionofhiv AT cazorlalunaraul tenofovirhotmeltgranulationusinggeluciretodevelopsustainedreleasevaginalsystemsforweeklyprotectionagainstsexualtransmissionofhiv AT martinillanaaraceli tenofovirhotmeltgranulationusinggeluciretodevelopsustainedreleasevaginalsystemsforweeklyprotectionagainstsexualtransmissionofhiv AT ruizcaroroberto tenofovirhotmeltgranulationusinggeluciretodevelopsustainedreleasevaginalsystemsforweeklyprotectionagainstsexualtransmissionofhiv AT penajuan tenofovirhotmeltgranulationusinggeluciretodevelopsustainedreleasevaginalsystemsforweeklyprotectionagainstsexualtransmissionofhiv AT veigamariadolores tenofovirhotmeltgranulationusinggeluciretodevelopsustainedreleasevaginalsystemsforweeklyprotectionagainstsexualtransmissionofhiv |